PACB Nasdaq Laboratory Analytical Instruments Financials FY2016βFY2025
Pacific Biosciences Of California, Inc. had $160M of revenue in fiscal 2025, up 3.9% on the year before. Over five years, revenue changed +15.2% a year on average.
Last close Β· Oct 23, 2026
$2.11
2.4%Hi! I read Pacific Biosciences Of California, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+3.9%
Only a little. Sales grew 3.9% last year.
Does it make a profit?
β341.5%
No. It lost money last year.
Does profit turn into cash?
β71.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Pacific Biosciences Of California, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 30, 2026 | Q2 '26 | Time not announced | 8-K β |
| May 7, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 5, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 7, 2025 | Q2 '25 | After the market closes | 8-K β |
| Apr 9, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Jan 14, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 5, 2024 | Q3 '24 | Time not announced | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Pacific Biosciences Of California, Inc. had $160M of revenue in fiscal 2025, up 3.9% on the year before. Over five years, revenue changed +15.2% a year on average. Its operating margin was β346.2%, down 38.2Β pts: of every 100 in sales, about β346 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Pacific Biosciences Of California, Inc. lost $546M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$114M in fiscal 2025, β71.2% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Pacific Biosciences Of California, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.0B | $772M | $631M | $390M | $280M |
| Debt incl. finance leases | $898M | $899M | $0.5M | $0.0M | β |
| Debt / equity | 1.1x | 1.6x | 0.0x | 0.0x | β |
| Interest coverage | β16.8x | β20.9x | β23.3x | β35.4x | β79.6x |
| Current ratio | 15.4x | 3.2x | 7.8x | 7.5x | 5.1x |
| Quick ratio | 15.0x | 3.0x | 7.2x | 6.6x | 4.5x |
| Total assets | $2.0B | $1.8B | $1.7B | $1.3B | $784M |
| Total liabilities | $1.2B | $1.2B | $1.0B | $754M | $779M |
| Shareholders' equity | $791M | $563M | $701M | $507M | $5.3M |
| Net debt (β = net cash) | β$147M | $126M | β$631M | β$390M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Pacific Biosciences Of California, Inc. passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 9 | 4 / 9 | 4 / 9 | 5 / 8 | 3 / 8 | 2 / 9 | 5 / 9 | 3 / 9 | 3 / 8 |
| Accruals ratio | β4.7% | β17.5% | β23.0% | β3.7% | 3.5% | β5.8% | β2.7% | β2.7% | β6.9% | β42.6% |
| Altman Z'' | β16.84 | β19.21 | β16.62 | β26.02 | β0.35 | 1.36 | β1.32 | β1.59 | β5.15 | β13.42 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $90.7M | $93.5M | $78.6M | $90.9M | $78.9M | $131M | $128M | $201M | $154M | $160M |
| Gross profit | $44.2M | $34.7M | $25.1M | $34.6M | $32.6M | $58.9M | $49.0M | $52.8M | $37.3M | $45.8M |
| Research and development | $67.6M | $65.3M | $62.6M | $59.6M | $64.2M | $113M | $193M | $187M | $135M | $97.3M |
| Operating income | β$71.2M | β$89.8M | β$101M | β$101M | β$104M | β$210M | β$307M | β$334M | β$474M | β$554M |
| Interest expense | $3.2M | $2.9M | $2.4M | $2.6M | $0.3M | $12.5M | $14.7M | $14.3M | $13.4M | $7.0M |
| Pretax income | β$74.0M | β$92.7M | β$103M | β$84.1M | $29.4M | β$275M | β$314M | β$318M | β$310M | β$546M |
| Income tax | β | β | β | β | β | β$93.6M | $0.0M | β$11.4M | $0.3M | $0.3M |
| Net income | β$74.4M | β$92.2M | β$103M | β$84.1M | $29.4M | β$181M | β$314M | β$307M | β$310M | β$546M |
| Net income to common | β | β | β | β | β | β | β$314M | β$307M | β$310M | β$546M |
| Diluted EPS | β$0.83 | β$0.87 | β$0.76 | β$0.55 | $0.17 | β$0.89 | β$1.40 | β$1.21 | β$1.59 | β$1.82 |
| Diluted shares | 0.09B | 0.11B | 0.14B | 0.15B | 0.17B | 0.20B | 0.22B | 0.25B | 0.29B | 0.30B |
| Cash flow | ||||||||||
| Cash from operations | β$67.9M | β$67.5M | β$66.4M | β$78.3M | $19.5M | β$111M | β$263M | β$259M | β$206M | β$111M |
| Capital expenditure | $8.2M | $10.4M | $1.9M | $2.8M | $1.0M | $5.9M | $16.8M | $8.8M | $6.2M | $2.7M |
| Free cash flow | β$76.1M | β$78.0M | β$68.3M | β$81.1M | $18.5M | β$117M | β$280M | β$268M | β$212M | β$114M |
| Depreciation and amortization | $3.9M | $8.4M | $7.2M | $7.3M | $6.4M | $7.2M | $9.5M | $11.5M | $13.8M | $13.0M |
| Stock-based compensation | $19.6M | $20.4M | $23.2M | $16.4M | $17.5M | $73.4M | $78.6M | $72.1M | $71.0M | $41.7M |
| Acquisitions | β | β | β | β | β | β | $0.0M | $0.1M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $72.0M | $62.9M | $102M | $49.1M | $319M | $1.0B | $772M | $631M | $390M | $280M |
| Total debt | $16.1M | $13.6M | $14.7M | $15.9M | β | $898M | $899M | $0.5M | $0.0M | β |
| Current assets | $109M | $102M | $132M | $81.0M | $356M | $1.1B | $852M | $742M | $496M | $375M |
| Current liabilities | $33.8M | $28.6M | $26.9M | $49.2M | $38.5M | $71.7M | $263M | $95.0M | $66.3M | $72.8M |
| Inventory | $15.6M | $23.1M | $17.9M | $13.3M | $14.2M | $24.6M | $50.4M | $56.7M | $58.8M | $49.3M |
| Property and equipment, net | $14.6M | $37.9M | $34.1M | $30.1M | $24.9M | $32.5M | $41.6M | $36.4M | $30.5M | $24.1M |
| Goodwill | β | β | β | β | β | $410M | $410M | $462M | $318M | $318M |
| Intangible assets | β | β | β | β | β | $411M | $410M | $457M | $390M | $15.1M |
| Total assets | $138M | $144M | $170M | $148M | $414M | $2.0B | $1.8B | $1.7B | $1.3B | $784M |
| Total liabilities | $53.2M | $58.0M | $56.2M | $93.1M | $78.5M | $1.2B | $1.2B | $1.0B | $754M | $779M |
| Preferred stock | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $84.7M | $86.1M | $114M | $54.9M | $335M | $791M | $563M | $701M | $507M | $5.3M |
| Margins | ||||||||||
| Gross margin | 48.7% | 37.1% | 31.9% | 38.0% | 41.3% | 45.1% | 38.2% | 26.3% | 24.2% | 28.6% |
| Operating margin | β78.5% | β96.1% | β128.4% | β110.6% | β132.3% | β161.2% | β239.4% | β166.8% | β308.0% | β346.2% |
| EBITDA margin | β74.3% | β87.0% | β119.3% | β102.6% | β124.2% | β155.7% | β232.0% | β161.1% | β299.0% | β338.0% |
| Net margin | β82.0% | β98.6% | β130.4% | β92.6% | 37.3% | β138.9% | β244.9% | β153.0% | β201.2% | β341.5% |
| FCF margin | β83.9% | β83.4% | β86.8% | β89.3% | 23.4% | β89.7% | β218.2% | β133.7% | β137.8% | β71.2% |
| Returns | ||||||||||
| Return on capital | β195.5% | β192.4% | β302.6% | β366.2% | β | β25.8% | β35.2% | β375.4% | β321.2% | β |
| Return on capital employed | β68.4% | β77.8% | β70.4% | β101.7% | β27.8% | β10.9% | β20.4% | β20.3% | β39.7% | β77.9% |
| Return on equity | β87.8% | β108.0% | β102.5% | β99.6% | 15.1% | β32.2% | β46.4% | β48.5% | β51.3% | β213.5% |
| Return on assets | β53.9% | β65.4% | β65.3% | β52.9% | 10.5% | β15.0% | β16.7% | β17.5% | β20.6% | β53.4% |
| Return on tangible equity | β87.8% | β107.1% | β89.9% | β153.2% | 8.8% | β | β | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | 3.0% | β15.9% | 15.6% | β13.2% | 65.4% | β1.7% | 56.3% | β23.2% | 3.9% |
| Net income growth | β | β | β | β | β | β716.3% | β | β | β | β |
| EPS growth | β | β | β | β | β | β623.5% | β | β | β | β |
| FCF growth | β | β | β | β | β | β734.3% | β | β | β | β |
| Share count change | β | 18.5% | 27.8% | 12.9% | 14.7% | 16.7% | 10.0% | 12.9% | 13.7% | 4.0% |
| Financial health | ||||||||||
| Debt / equity | 0.2x | 0.2x | 0.1x | 0.3x | β | 1.1x | 1.6x | 0.0x | 0.0x | β |
| Interest coverage | β22.0x | β30.7x | β41.7x | β38.5x | β391.0x | β16.8x | β20.9x | β23.3x | β35.4x | β79.6x |
| Current ratio | 3.2x | 3.5x | 4.9x | 1.6x | 9.2x | 15.4x | 3.2x | 7.8x | 7.5x | 5.1x |
| Quick ratio | 2.8x | 2.7x | 4.2x | 1.4x | 8.9x | 15.0x | 3.0x | 7.2x | 6.6x | 4.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 9.0% | 11.2% | 2.4% | 3.1% | 1.3% | 4.5% | 13.1% | 4.4% | 4.0% | 1.7% |
| Stock comp / revenue | 21.6% | 21.8% | 29.4% | 18.0% | 22.2% | 56.2% | 61.3% | 36.0% | 46.1% | 26.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 4.0 | 5.0 | 3.0 | 2.0 | 5.0 | 3.0 | 3.0 |
| Altman Z'' | β16.8 | β19.2 | β16.6 | β26.0 | β0.3 | 1.4 | β1.3 | β1.6 | β5.1 | β13.4 |
| Accruals ratio | β4.7% | β17.5% | β23.0% | β3.7% | 3.5% | β5.8% | β2.7% | β2.7% | β6.9% | β42.6% |
Source: SEC EDGAR XBRL filings (CIK 0001299130). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
